Ignite Creation Date:
2024-05-05 @ 5:30 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00472602
Status:
COMPLETED
Last Update Posted:
2019-01-31
First Post:
2007-05-10
Brief Title:
Pathogenesis of Liver Fluke Induced Cancer in Thailand
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
National Institute of Allergy and Infectious Diseases NIAID
Study Overview
Official Title:
Pathogenesis of Liver Fluke Induced Cancer in Thailand
Status:
COMPLETED
Status Verified Date:
2014-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Opisthorchis viverrini OV is a parasite that individuals get from eating raw fish Infections with this parasite have been associated with liver abnormalities that sometimes lead to bile duct cancer The purpose of this study is to find out how many people in several areas of the Khon Kaen province are infected with OV what affect this parasite has on the liver how the immune system reacts to infection with this parasite and how the liver is 12 months after being treated for this parasite Study participants will include 6000 volunteers ages 20-60 living in villages surrounding Khon Kaen that have large numbers of people infected with OV Study procedures will include a stool sample an ultrasound sound waves bounced off internal organs to create a picture and a blood sample Individuals found to test positive for the parasite will be treated at their local primary health care unit Participants will be involved in study procedures for up to 12 months
Detailed Description:
Liver fluke infection caused by Opisthorchis viverrini OV is a major public health problem in parts of East Asia In Thailand an estimated 6 million are people infected with OV Experimental and epidemiological evidence strongly implicate OV infection in the etiology of cholangiocarcinoma CCA Studies have shown 10-20 of OV-infected persons have advanced periportal fibrosis HBA that progresses to CCA OV infection may cause inflammation of the bile ducts that results in DNA damage of the epithelium and subsequent malignant transformation The primary objective of this study is to determine if in-vitro levels of inflammatory cytokines induced by crude antigen extracts of OV are associated with the hepatobiliary abnormalities known to progress to CCA in OV-infected adults aged 20 to 60 years of age The secondary objective is to determine if in-vitro levels of inflammatory cytokines induced by crude antigen extracts of OV in adults with hepatobiliary abnormalities change 12 months after treatment with praziquantel and if these changes are associated with persistent advanced fibrosis grade 2 or 3 as determined by ultrasonography The primary outcome measure is elevated levels of inflammatory cytokines such as TNF-alpha induced by OV infection are associated with a 50 greater risk OR 150 of having advanced fibrosis grade 2 or 3 as determined by ultrasonography The secondary outcome measure is elevated levels of inflammatory cytokines 12 months after treatment for OV infection are associated with a 50 greater risk OR 150 of maintaining the advanced fibrosis that is known to progress to CCA over this time period District health outposts reporting greater than or equal to 20 percent prevalence of OV infection among adults will be identified whereupon males and females 20 to 60 years of age will be screened for OV infection Study sites in Thailand will be districts of Ban Pai Chonnabot Muncha Khiri and Kok Pochai regions along the drainage of the Chi River in the vicinity of the regional capitol Khon Kaen city A recruitment ceiling of 20000 individuals will be established to screen for infection with OV with 6000 enrolled in the observational and longitudinal parts of the study OV-infected individuals will receive an ultrasound examination that will be graded as either HBA positive advanced fibrosis or HBA negative non-advanced fibrosis Over a 24 month period 1116 OV-infected individuals who are HBA positive will be recruited The first 484 OV-infected individuals with HBA will be age and sex matched with OV-infected individuals from the same region who are HBA negative Blood samples will be drawn from all volunteers and used in immunological evaluations of OV infection in relation to HBA status This will constitute the observation stage of the study The 1116 OV-infected individuals with HBA will be followed for an additional 12 months with an ultrasound exam and a blood draw This will constitute the longitudinal stage of the study All volunteers will then be treated for OV infection with praziquantel
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None